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Abstract. Fetuin-A is a liver-synthesized protein that is secreted into serum. Transforming 
growth factor-β (TGF-β) is a polypeptide member of the TGF-β superfamily of cytokines. 
The purpose of this study is to evaluate the effects of lifestyle modification and metformin 
on fetuin-A and Transforming Growth Factor-ß (TGF- ß) in metabolic syndrome (MetS). 
Forty MetS subjects were randomly assigned to treatment with placebo (n=20) or 
metformin (n=20) in addition to lifestyle modification for 12 weeks. All 40 participants 
completed the study. After 12 weeks, both groups had significant reductions in weight, 
body mass index (BMI), waist circumference (WC), systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) (all p<0.001). The placebo group also had significant 
improvement in fasting plasma glucose (FPG)  and C-reactive protein (CRP) (p<0,001 ; 
p<0.05 respectively). Weight, BMI, WC, FPG, 2-hour postprandial glucose (2h-PPG), high 
density lipoprotein cholesterol (HDL-C), triglycerides (TG), fetuin-A and TGF- ß in the 
metformin group decreased significantly compared to the placebo group. Reduction of 
plasma fetuin-A was significantly associated with TG in the metformin group. Lifestyle 
modification and treatment with metformin for 12 weeks improved cardio-metabolic risk 
factors in MetS and reduced fetuin-A levels. 
Keyword: Metabolic syndrome, lifestyle modification, fetuin-A, TGF- ß 
Abstrak. Fetuin-A adalah protein yang disintesis hati yang disekresikan ke dalam serum. 
Transforming growth factor-β (TGF-β) adalah anggota polipeptida dari superfamili TGF-β 
sitokin. Tujuan dari penelitian ini adalah untuk mengevaluasi pengaruh modifikasi gaya 
hidup dan metformin pada fetuin-A dan Transforming Growth Factor-ß (TGF- ß) pada 
sindrom metabolik (MetS). Empat puluh subyek MetS secara acak ditugaskan untuk 
pengobatan dengan plasebo (n = 20) atau metformin (n = 20) di samping modifikasi gaya 
hidup selama 12 minggu. Semua 40 peserta menyelesaikan studi. Setelah 12 minggu, kedua 
kelompok mengalami penurunan berat badan yang signifikan, indeks massa tubuh (BMI), 
lingkar pinggang (WC), tekanan darah sistolik (SBP) dan tekanan darah diastolik (DBP) 
(semua p <0,001). Kelompok plasebo juga mengalami peningkatan yang signifikan dalam 
glukosa plasma puasa (FPG) dan protein C-reaktif (CRP) (masing-masing p <0,001; p 
<0,05). Berat badan, BMI, WC, FPG, glukosa postprandial 2 jam (2h-PPG), kolesterol 
lipoprotein densitas tinggi (HDL-C), trigliserida (TG), fetuin-A dan TGF-ß pada kelompok 
metformin menurun secara signifikan dibandingkan dengan kelompok plasebo. 
Pengurangan fetuin-A plasma secara bermakna dikaitkan dengan TG pada kelompok 
metformin. Modifikasi dan pengobatan gaya hidup dengan metformin selama 12 minggu 
meningkatkan faktor risiko kardio-metabolik dalam MetS dan mengurangi kadar fetuin-A.    
Kata Kunci: Sindrom metabolik, modifikasi gaya hidup, fetuin-A, TGF- ß. 
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1 Introduction 
The Metabolic Syndrome (MetS) represents a combination of cardio-metabolic risk factor 
determinants including central adiposity, insulin resistance, glucose intolerance, dyslipidemia, 
non-alcoholic fatty liver disease (NAFLD) and hypertension. It is rapidly increasing in 
prevalence worldwide as a consequence of the obesity epidemic. As a result, MetS will have a 
considerable impact on the global incidence of cardiovascular disease and type 2 diabetes 
(T2DM) (Bruce et al., 2009). Insulin resistance is thought to be the primary underlying 
abnormality leading to MetS (Reaven, 1988) 
Fetuin-A (also known as human protein alpha-2-Heremans-Schmid-glycoprotein, AHSG) and 
other circulating proteins have been shown to be involved in the regulation of insulin sensitivity. 
Fetuin-A is a liver-synthesized protein that is secreted into serum. It can bind the insulin 
receptor and inhibit insulin signaling in skeletal muscle and hepatocytes, inhibiting insulin 
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signal transduction and resulting in insulin resistance in the target tissues (Srinivaset al., 1993). 
In humans, higher levels of fetuin-A are associated with higher TG, low-density lipoprotein 
cholesterol (LDL-C), BMI, and insulin resistance (Stefanet al., 2006). Higher fetuin-A 
concentrations were associated with accumulation of visceral adipose tissue, a major component 
of the MetS (Ix et al., 2009). The link between fetuin-A, obesity, insulin resistance, NAFLD, 
and MetS in humans is less clear. Some studies in adults have reported significant associations 
between fetuin-A, NAFLD and insulin resistance (Mori et al., 2006). Most of these studies were 
cross-sectional and limited by many confounders. Longitudinal studies are preferable to clarify 
these metabolic relationships.  
Transforming growth factor-β (TGF-β) is a polypeptide member of the TGF-β superfamily of 
cytokines. The TGF-β superfamily consists of TGF-β, activins, inhibins, growth differentiation 
factors, and bone morphogenetic proteins (BMPs). The TGF-β superfamily proteins share 
common sequences and motifs to exert their various biological actions, including cell growth, 
differentiation, proliferation, migration, adhesion, apoptosis, and extracellular matrix (ECM) 
production. Metabolic syndrome is mostly characterized as visceral fat obesity with multiple 
cardiovascular risk factors, including elevated blood pressure, hyperglycemia, and dyslipidemia. 
Therefore, an understanding of the molecular mechanism by which visceral obesity is promoted 
is essential for preventing cardiovascular events in individuals with MetS (Ken-ichiet al., 2011). 
Lifestyle modifications (LSM) to address overweight, physical inactivity and an atherogenic 
diet have been recommended as a foundation for the management ofMetS(Eckelet al., 2005). 
However, LSM alone is often unable to achieve clinically meaningful weight loss (UKPDS, 
1998). 
Metformin, a biguanide oral antidiabetic agent, has been shown to reduce weight, 
hyperinsulinemia and hyperglycemia in adult patients with T2D. It is recommended as first-line 
pharmacotherapy in overweight and obese T2D patients (Sharoffet al., 2010). While metformin 
has been found to attenuate the insulin-sensitizing effect of exercise, it has been found to have 
beneficial effects on inhibition of platelet aggregation, antioxidant activity, weight reduction, 
lipid parameters (total cholesterol, HDL-C, LDL-C and TG) and arterial hypertension (Gluecket 
al., 2001, Wulffeléet al., 2004, Pasqualiet al., 2000). Metformin can be given safely to 
euglycemic patients, as it does not induce hypoglycemia (Linet al., 2000). Furthermore, in ob/ob 
mice, a model of hepatic steatosis, metformin reversed hepatomegaly, hepatic fat accumulation 
and ALT abnormalities by reducing hepatic tumor necrosis factor-α (TNF-α) expression (WHO, 
2004). 
The aim of this study was to assess the effect of LSM on cardio-metabolic risk factors, fetuin-A 
and TGf-ß levels with or without metformin in relation to improvement of insulin sensitivity in 
patients with the MetS. 
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2 Method 
Study subjects who met the 2006 IDF definition of the metabolic syndrome were recruited from 
the nurse of H. Adam Malik Hospital in Medan, Indonesia. The criteria included central obesity 
(WC of ≥ 90 cm in men and ≥ 80 cm in women of Asian ethnicity) plus any 2 of the following 4 
factors: elevated triglycerides (≥ 150 mg/dL) or specific treatment for this lipid abnormality, 
reduced HDL-C (< 40 mg/dL in men and < 50 mg/dL in women) or specific treatment for this 
lipid abnormality, elevated BP blood pressure (SBP ≥130 mmHg or DBP ≥ 85 mmHg) or 
treatment of previously diagnosed hypertension, and elevated FPG (≥ 100 mg/dL) or previously 
diagnosed type 2 diabetes (WHO, 2004, IDF, 2006). Exclusion criteria included smoking, 
known cardiovascular disease or any major illness, and use of medication that could affect 
laboratory test results. Forty subjects gave their full informed consent to participate and undergo 
LSM for 12 weeks. They were assigned randomly to treatment with either placebo or 
metformin. Each participant was advised to take one capsule three times a day after meal. For 
the placebo group, the capsule contained calcium gluconate 500 mg. For the metformin group, 
the capsule contained metformin 500 mg. No vitamins or other nutritional supplements were 
prescribed. Prior to initiation and during the study, all the participants discussed LSM including 
diet and physical activity with a trained health nurse. To facilitate behavior change, each 
participant received an instructional leaflet and a diary to record behavioral performance, diet, 
physical activity, WC and weight. Every week, all participants attended a follow-up meeting for 
confirmation of compliance and monitoring of any health and safety problems related to 
behavioral changes and treatment. 
2.1 Anthropometric and body composition measurements 
Baseline anthropometric measures were taken. The following BMI categories appropriate for 
Asians were used: underweight, BMI < 18.5 kg/m2 ; normal, 18.5 to 22.9 kg/m2; overweight, 
23.0 to 24.9 kg/m2; obese class I, 25.0 to 29.9 kg/m2; obese class II BMI ≥ 30.0 kg/m2 (Misraet 
al., 2007). BMI was measured every week to assess the immediate effect of LSM. 
2.2 Diet and exercise regimen 
For 12 weeks, all subjects followed a weight maintenance diet (total calories per day divided 
into 55 to 60% carbohydrate, 15 to 20% protein and 20 to 25% fat) and moderate exercise in 
accordance with recommendations from the Endocrinology Association of Indonesia (Perkeni, 
2011). All subjects were free living and consumed self-selected foods from a list of food 
replacements made according to their individual dietary habits. The dietitian reviewed the 
participants’ diet on a weekly basis to ensure compliance.  
The exercise program consisted of moderate aerobic exercise at least 3 times per week, with a 
minimum of 30 minutes for each session (Perkeni, 2011). Each session included 5 minutes of 
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warm-up, 20 minutes of main exercises, and 5 minutes of relaxation exercises. Each training 
session was supervised by a physiotherapist.  
2.3 Blood Pressure and Blood Sample Analysis 
Blood pressure was averaged from two measurements using a mercurial sphygmomanometer 
after a 10 minute rest. All subjects reported for blood sampling in the morning after an 
overnight fast. Blood samples were centrifuged for 15 minutes, after which plasma- and serum-
containing tubes were stored at -20°C until analysis. Blood glucose was measured by 
photometer autoanalyzer Modular P800.Plasma HDL-C, LDL-C and TG were measured using 
ARCHITECT ci8200 (Abbott Diagnostics, USA). High-sensitivity CRP was measured by 
sensitive immunoassay using Immulite® 1000 Analyzer System (Siemens Healthcare, 
Germany). HbA1c measurement was done by high-performance liquid chromatography (HPLC) 
using D-10™ (Bio-Rad, USA). Homeostatic model assessment of insulin resistance (HOMA-
IR) was computed using the formula: 
HOMA-IR = FPG x fasting serum insulin / 22.5 
Where FPG is expressed in mmol/L and fasting serum insulin in mU/L. Fetuin-A determination 
was performed by human fetuin-A enzyme immunoassay and TGF-ß also by enzyme 
immunoassay. 
3 Statistical Analysis 
Data were presented as mean ± SD. Normality assumption of data from the placebo group and 
metformin group was evaluated and confirmed using Shapiro-Wilk normality test. Differences 
between and within groups were tested using the dependent t-test and independent sample t-test. 
Abnormal data were tested using Mann-Whitney U test, Wilcoxon testand Spearman’s 
correlation coefficient test. Two-sided p-values of less than 0.05 were regarded as statistically 
significant. The data were analyzed using SPSS software. 
4 Results 
All 40 participants completed the study for 12 weeks. Analysis of baseline characteristics 
showed no significant differences in selected cardio-metabolic risk factors and fetuin-A (Table 
1). After 12 weeks, both groups had reductions in weight, BMI, WC, SBP, and DBP. Reduction 
in CRP was also found in the placebo group; fetuin-A was reduced in the metformin group. 
Compared to placebo, weight, BMI, WC, FPG, 2h-PPG, HDL-C and TG had decreased 
significantly in the metformin group (Table 2). 
 
 
Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease Vol. xx, No. xxx, year Page Number                                                            
Table 1 Baseline Characteristic 
Characteristicts Placebo group (n =  
20) 
Mean (SD) 
Metformin group (n = 
20) 
Mean (SD) 
P 
Age, yr  40.1 (5.78) 42.7 (5.2) 0.149 
Weight, kg 77.6 (11.0) 81.4 (14.6) 0.354 
BMI, kg/m² 32.1 (4.1) 34.2 (5.6) 0.180 
WC, cm 95.7 (7.3) 97.9 (11.5) 0.449 
SBP, mmHg 123.5 (11.4) 127.0 (20.3) 0.989 
DBP, mmHg 82.2 (10.5) 80.8 (11.0) 0.495 
HDL-C, mg/dL 46.4 (8.5) 48.9 (16.4) 0.968 
TG, mg/dL 147.5 (30.6) 152.3 (66.9) 0.799 
FPG, mg/dL 83.4 (10.6) 84.9 (8.9) 0.341 
2h-PPG, mg/dL 114.9 (35.4) 105.1 (22.4) 0.602 
HOMA-IR  1.13 (0.94)                1.0 (0.6) 0.700 
CRP,  mg/dL 3.6 (2.5) 3.9 (2.4) 0.699 
Fetuin-A, µg/mL 461.4 (74.6) 459.0 (62.8) 0.911 
TGF-ß1, pg/mL 47479,34 (6942.01) 45272.06 (3711.22) 0.380 
 
 
 
 
 
 
 
Table 2   Change in selected cardio-metabolic risk factors from baseline and at 12 weeks, 
N= 40 
 
Parameter Placebo group 
(n=20) 
Metformin group 
(n=20) 
P 
 Baselin
e 
12 
weeks 
Defferen
ce 
P Baseline 12 
weeks 
Defferen
ce 
P  
Weight 
(SD), kg 
77.6 
(11.0) 
75.2 
(10.8) 
-2.3 0.001
** 
81.4 
(14.6) 
77.4 
(14.5) 
-3.9 0.001
** 
0.001
** 
BMI (SD), 
kg/m² 
32.1 
(4.1) 
30.9 
(4.1) 
-1.1 0.001
** 
342 (5.6) 32.4 
(5.6) 
-1.8 0.001
** 
0.002
** 
WC (SD), 
cm 
95.7 
(7.3) 
89.9 
(7.5) 
-5.8 0.001
** 
97.9 
(11.5) 
91.8 
(10.7) 
-6.2 0.001
** 
0.047
* 
SBP (SD), 
mmHg 
123.5 
(11.4) 
114.0 
(8.2) 
-9.5 0.007
** 
127.0 
(20.3) 
112.8 
(8.5) 
-14.3 0.001
** 
0.160 
DBP (SD), 
mmHg 
82.2 
(10.5) 
69.0 
(5.5) 
-31.8 0.001
** 
80.6 
(11.0) 
67.5 
(7.2) 
-13.3 0.001
** 
0.089 
HDL-C 
(SD), mg/dL 
46.4 
(8.5) 
45.3 
(10.0) 
-1.1 0.628 489 (16.4) 45.5 
(9.8) 
-2.4 0.653 0.043
* 
TG (SD), 
mg/dL 
147.5 
(50.5) 
153.3 
(67.9) 
5.8 0.634 152.3 
(66.9) 
149.0 
(102.4) 
-3.3 0.147 0.045 
FPG (SD), 
mg/dL 
83.4 
(10.6) 
91.7 
(20.6) 
8.3 0.001
** 
84.9 (8.9) 87.7 
(10.7) 
2.8 0.305 0.013
* 
2h-PPG 
(SD), mg/dL 
114.9 
(35.4) 
112.5 
(37.7) 
-2.5 0.717 105 (22.4) 102.3 
(19.3) 
-2.8 0.491 0.007
** 
HOMA-IR 
(SD) 
1.13 
(0.94) 
1.68 
(0.25) 
-0.5 0.610 1.03 
(0.61) 
1.03 
(0.4) 
0 0.956 1.000 
CRP (SD), 
mg/dL 
3.6 (2.5) 3.0 (2.2) -0.6 0.048
* 
3.9 (2.4) 3.5 
(1.9) 
-0.6 0.327 0.133 
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Fetuin-A 
(SD), µg/mL 
461.4 
(74.6) 
42.6 
(84.8) 
-34.8 0.158 459.0 
(62.8) 
398.1(
101.4) 
-610 0.005
** 
0.477 
TGF-ß1 
(SD), pg/mL 
47479.3
4(6942.
01) 
47346.6
9 
(6654.1
1) 
-132.65 1.000 45272.06 
(3711.22) 
4458.7
1 
(8232.
4) 
-1013.35 0,661 0.353 
 
5 Discussion 
Obesity is the most common risk factor for the MetS and NAFLD (Reinehet al., 2008). As 
suggested by novel evidence, hepatocytes from fatty liver release factors called hepatokines 
(e.g., fetuin-A, sex hormone-binding globulin) into the circulation that are directly involved in 
local pathogenesis, systemic inflammation and hepatic insulin resistance (Reavenet al., 1988). 
Thefetuin-A levels of obese children are apparently similar to those of adults (Ohkawaraet al., 
2007). A study by Mori and colleaguesdid not find a significant association between fetuin-A 
and insulin resistance in type 2 diabetic subjects (Mori et al., 2006).In contrast, other studies 
demonstrated a relationship between fetuin-A and insulin resistance in adults without T2D 
(Stefanet al., 2006).Fetuin-A concentrations decreased significantly in obese children after 
substantial weight loss after 1 year, but was apparently unchanged in those who did not lose 
weight (Ohkawaraet al., 2007). Our study found that fetuin-A decreased significantly with LSM 
and metformin treatment for 12 weeks, possibly associated with weight reduction.  
A recent systematic review showed a dose-response effect of aerobic exercise on visceral 
adiposity, but the ability of exercise to reduce visceral adipose tissue was less robust in those 
with metabolic disorders (Wing et al., 2001). It remains unclear if the same dose-response effect 
on central adiposity will also be seen in those with MetS. Nevertheless, during weight 
maintenance, regular exercise still has an important role in abdominal fat loss and may help 
prevent weight regain in those who have successfully lost weight (Ross et al., 2004). However, 
even in the absence of weight loss, exercise has been shown toreduce visceral adipose tissue 
(Stone et al., 2005). Our study demonstrated that weight, BMI and WC decreased significantly 
in the course of 12 weeks of LSM in both groups.  
The National Cholesterol Education Program Adult Treatment Panel III (NCEP:ATP-III) 
recommends LDL-C reduction as the primary treatment goal for CVD risk reduction. 
Therapeutic lifestyle changes, particularly improvement in physical activity and weight 
management, need to be instituted in those individuals with the MetS to address elevated TG 
and low HDL-C (Kelley, 2007). Although aerobic exercise training has generally been shown to 
increase HDL-C and decrease TG, its effects on LDL-C has been mixed (Kodamaet al., 2007, 
Stefanicket al., 1998). Beneficial effects of exercise training on lipids and lipoproteins may have 
additional impact when combined with dietary modification and weight loss (Wheltonet al., 
2002). Our study demonstrated HDL-C and TG did not decrease significantly in the course of 
12 weeks of LSM on both groups.  
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A recent meta-analysis of randomized controlled trials studying the effect of aerobic exercise on 
BP showed reduction in systolic and diastolic BP by approximately 3.8 and 2.6 mmHg, 
respectively (Bacon et al., 2004). Although the effect of aerobic exercise on blood pressure is 
small and not consistently observed in all studies, there may be additional benefit when 
combined with dietary modification and/or weight loss (Cornieret al., 2008). Our study 
demonstrated significant reductions in systolic and diastolic BP in both groups in the course of 
12 weeks of LSM.  
Insulin resistance is another core component of MetS that requires careful attention. Weight loss 
and LSM can lead to clinically meaningful improvements in insulin sensitivity and should be 
considered the primary therapeutic options for treating insulin resistance. The difficulties and 
frustrations associated with weight loss efforts and LSM have driven the demand for using 
pharmaceutical agents that target insulin resistance in a more direct fashion. The exact role for 
these agents is less clear. Several randomized controlled trials have shown that agents targeting 
insulin resistance can help prevent the progression to T2D in individuals with impaired glucose 
tolerance (IGT). These studies did not directly target individuals with the MetS. It is unclear 
whether these agents truly prevent progression to T2D or simply treat glucose intolerance or 
mild hyperglycemia. In addition, studies have not clearly shown whether these agents improve 
cardiovascular outcomes. As with weight loss medications, the goals for the use of agents 
targeting insulin resistance must be clear (Hennigeet al., 2008). Our study demonstrated 
HOMA-IR did not decrease significantly in both groups.  
Fetuin-A induces low grade inflammation, which is also associated with MetS and an 
atherogenic lipid profile (Reinehret al., 2008, Ridker, 2001). Inflammation assessed by elevated 
CRP measurements has been linked to excess cardiovascular risk and MetS (Ridkeret al., 2003, 
Gonzálezet al., 2006). CRP is a general marker of inflammation, making it suitable to assess in 
individuals with the metabolic syndrome. Elevated levels of CRP are associated with increased 
WC, insulin resistance, BMI and hyperglycemia; and in the presence of more components of the 
MetS (Deepaet al., 2006, Guldikenet al., 2007, Bahiaet al., 2006, Gonzálezet al., 2006, 
Clearfield, 2005). Because MetS has been linked with a greater chance of future cardiovascular 
events, CRP levels may be an important independent predictor of unfavorable outcomes in those 
already with MetS (Van Dielenet al., 2004). There are, however, no currently recommended 
direct therapies targeting inflammation. LSM and weight loss result in decreased CRP 
concentrations, as does the treatment of the other associated comorbidities such as dyslipidemia, 
elevated blood pressure, insulin resistance and hyperglycemia (Devaraj, 2007, Knowleet al., 
2002). Our study observed CRP decreased significantly only in the placebo group.  
It has not been determined how the Pro 10 variant form of the TGF-β1 protein is linked to 
visceral adiposity and elevated levels of circulating insulin, there is a possibility that TGF-β1 is 
involved in the insulin resistance with obesity. Since macrophage infiltration into adipose tissue 
causes insulin resistance  and since coculture experiments with human adipocytes and 
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macrophages have shown that downstream effectors of TGF-β such as PAI-1, collagen VI, and 
phosphorylated Smad were increased in both macrophages and adipocytes, TGF-β has the 
potential for increasing insulin resistance (Ken-ichi, 2011). 
In experimental animal studies, Samad et al. reported enhancement of gene and protein 
expression of TGF-β1 in two strains of genetically obese mice (ob/oband db/db) compared with 
that in lean mice(Samad, 1997) and Raju et al. showed that an obese state increases levels of 
TGF-β1 but not TGF-β2 in platelets of Zucker rats, recognized as an experimental model of 
Mets (Raju, 2006). Moreover, Sciarretta et al. showed that serum levels of inflammatory 
markers, including Creactiveprotein, tumor necrosis factor-alpha and TGF-β, in hypertensive 
patients with MetS were significantly higher than those in patients without MetS (Ken-ichi, 
2011). 
6 Conclusion 
LSM decreased CRP, human fetuin-A concentrations, TGF-ß and selected cardio-metabolic risk 
factors in this 12-week study. These findings raise the possibility that fetuin-A may directly 
promote the MetS phenotype in humans and there is possibility that TGF-ß is involved in the 
insulin resistance with obesity. The selected cardio-metabolic factors significantly improved 
with metformin to the same degree as with the LSM. Longitudinal and larger scale studies are 
needed to evaluate the direction of the observed associations, the regulatory factors that alter 
serum fetuin-A concentrations, its effects on cardiovascular events, and the long-term effects of 
metformin on selected cardio-metabolic risk factors. 
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